打开APP

GSK治疗杜氏肌营养不良药物drisapersen三期研究失败

  1. drisapersen
  2. GSK
  3. 杜氏肌营养不良

来源:生物谷 2013-10-10 09:28

2013年10月9日讯 /生物谷BIOON/ --制药巨头葛兰素史克公司开发的用于治疗杜氏肌营养不良的药物drisapersen上周宣布失败。公司表示在分析数据后发现,此次三期研究未能达成任何有价值的研究结果。在这次长达48周的研究中,使用drisapersen的患者相比于安慰剂组未能有明显改善。

2013年10月9日讯 /生物谷BIOON/ --制药巨头葛兰素史克公司开发的用于治疗杜氏肌营养不良的药物drisapersen上周宣布失败。公司表示在分析数据后发现,此次三期研究未能达成任何有价值的研究结果。在这次长达48周的研究中,使用drisapersen的患者相比于安慰剂组未能有明显改善。尽管此次三期临床试验结果不尽理想,公司研究人员表示仍将深入分析研究结果以确定drisapersen是否仅对特定群体有效。(生物谷Bioon.com)

详细英文报道:

Over the weekend GlaxoSmithKline ($GSK) detailed the decisive failure of its ambitious Phase III study for drisapersen, a new drug designed to treat Duchenne muscular dystrophy. John Kraus, GSK's medical leader for drisapersen, unveiled more data from the failed study on the exon-skipping technology, which fell short not only on its primary endpoint for improved walking distances in a 6-minute test but also flunked out on three separate secondary endpoints, with the outcomes looking almost identical in each case with a placebo.

After 48 weeks of therapy, says Kraus, the drisapersen group suffered a decline in walking distance, just as the placebo arm did. The decline was 10.3 meters in the drug arm's favor, falling short of a significant improvement and well off the more than 30-meter improvement seen in Phase II. Using the North Star Ambulatory Assessment test, the placebo arm scored 6.7 compared to a close 7.2 score for drisapersen. A velocity test gauging the time to climb four stairs was also virtually identical--a 0.12 decline in the placebo arm and a 0.14 decline in the drug group. There was a near mirror-image decline in the rate of patients' 10-meter walk/run velocity gauge.

Kraus says the trial was well run and the quality outcomes they measured were good, providing a clear read out on the drug for the group they studied. Now investigators are going back over the data to see if a subset of patients benefited. And they are also running analyses on dystrophin expression to see how the therapy--in-licensed from the Dutch biotech Prosensa--influenced a key biomarker for the disease.

"We need to understand if there may be a subpopulation that could have derived a benefit from drisapersen," Kraus tells FierceBiotech. "We are currently running analyses to help us understand."

Subpopulation analysis is common in drug development, but it's far from ideal. A positive sign in a particular group might open the door to a new study geared for a narrow segment of the patient population, which has no meaningful therapy to rely on. But it's no guarantee of even limited success.

Investors have been paying particularly close attention to the drisapersen data to see how it might reflect on eteplirsen, a DMD drug in development at Sarepta ($SRPT). Sarepta shares have soared on the positive outcome seen in a very small study of the drug, and the biotech believes it has a shot at an accelerated approval based on that study. Right now, eteplirsen is the leading therapy in the DMD field, and there's nothing in GlaxoSmithKline's latest data that changes any of that.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->